# Study of SPARC1103 in Subjects With Spasticity

> **NCT02027025** · PHASE2 · COMPLETED · sponsor: **Sun Pharma Advanced Research Company Limited** · enrollment: 142 (actual)

## Conditions studied

- Spasticity

## Interventions

- **DRUG:** SPARC1103 low dose
- **DRUG:** SPARC1103 high dose
- **DRUG:** SPARC Placebo

## Key facts

- **NCT ID:** NCT02027025
- **Lead sponsor:** Sun Pharma Advanced Research Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-21
- **Primary completion:** 2017-04-28
- **Final completion:** 2017-04-28
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2019-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02027025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02027025, "Study of SPARC1103 in Subjects With Spasticity". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT02027025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*